In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until eventually disease progression or the participants are unable to tolerate the study drugs. Celastrol was discovered like a Myb inhibitor that suppressed C/EBPβ exercise and repressed https://abbv-744cancertreatmentcl03578.bloguerosa.com/31229931/getting-my-abbv-744-brd4-inhibitor-clinical-efficacy-in-refractory-cancers-to-work